Researchers said the majority of men with enlarged prostates and lower urinary tract symptoms reported better sleep that resulted in an improved quality of life after they underwent treatment with the procedure.
SurModics has announced enrolment of the first patient in an early feasibility study of its proprietary SurVeil drug-coated balloon (DCB). A press release states that this study is part of the company’s strategy to transform its medical device business from a provider of device coatings, to offering differentiated whole-product solutions to leading medical device customers.
At the 2016 Charing Cross Symposium (26–29 April, London, UK) and the International Vein Congress (28–30 April, Miami, USA) Medtronic unveiled clinical data for the VenaSeal closure system demonstrating consistent long-term durability and improved quality of life in patients with venous reflux disease.
In a study comparing multiplanar venography to intravascular ultrasound (IVUS) for diagnosing common or external iliac and common femoral vein stenosis, IVUS imaging was found to change both the treatment plan in 60/100 patients and the number of stents placed in 50/100 patients. Presenter Paul Gagne (Darien, USA) maintained that “without IVUS, iliofemoral vein occlusive disease would have been undertreated in the majority of patients studied”.
SurModics has announced enrolment of the first patient in an early feasibility study of its proprietary SurVeil drug-coated balloon (DCB). A press release states that this study is part of the company’s strategy to transform its medical device business from a provider of device coatings, to offering differentiated whole-product solutions to leading medical device customers.
A study conducted at St Thomas’ Hospital, London, UK, indicates that the VeinCLEAR catheter (RF Medical) produces good results when used in radiofrequency ablation in the treatment of lower extremity superficial venous insufficiency. The study team, led by Adam M Gwozdz, now suggest that “Long-term evaluation of this device is now needed to ensure that these encouraging early results are maintained.”
Endologix has received CE mark for the next-generation Nellix Endovascular Aneurysm Sealing (EVAS) system. The first procedures with the system were performed by associate professor Andrew Holden and Andrew Hill at Auckland City Hospital, Auckland, New Zealand.
Stents, heart valves, ventricular assist devices, and extracorporeal support systems, as well as vascular grafts and access catheters devices, are prone to failure due to the body’s responses at the blood-material interface; clots can form and inflammatory reactions can prevent the device from performing as indicated. Currently, when this occurs, the only solution is to replace the device.
Psoriasis sufferers may face a higher risk of developing abdominal aortic aneurysms, according to new research in Arteriosclerosis, Thrombosis and Vascular Biology, an American Heart Association journal.
Drug-eluting and plain balloon angioplasty produce similar results at three years when treating femoropopliteal in-stent restenosis, according to new data from the DEBATE-ISR trial.
The first patient suffering from post-thrombotic syndrome associated with venous outflow obstruction has been treated with the VICI VERTO VENOUS STENT system.
AV Medical Technologies has announced the culmination of a 30-patient study that evaluated the proprietary design of the Chameleon angioplasty balloon catheter.
QT Vascular has submitted an investigational device exemption (IDE) for permission to begin the pivotal study of the Chocolate Touch drug-coated balloon in the USA.
Medtronic has announced with several new presentations that showed durable and consistent clinical outcomes in the most challenging patients with peripheral artery disease. The new data, presented at the 2016 Charing Cross Symposium (26–29 April, London, UK), included the one-year results from the chronic total occlusion imaging cohort from the IN.PACT Global Study and the two-year gender and diabetic subgroup analyses from the pivotal IN.PACT SFA Trial.
Now that non-thrombotic iliac vein lesions (NIVLs) are more frequently recognised on modern imaging modalities, they are beginning to trigger a paradigm shift in standard vein work whereby there is now increasing emphasis on making sure that these patients do not have significant deep venous obstruction which must be taken into account when planning treatment.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos